DPx Holdings B.V. Launches New Operational Excellence Program, Driving Performance eXponentially
DPx Holdings B.V., a leading provider of custom manufacturing, technologies and development services to the pharmaceutical, biopharmaceutical and agrochemical industries, is launching a new, company-wide operational excellence program, Driving Performance eXponentially or DP^x. The program is built upon the strengths and success of existing programs and is a part of the integration results from the merger of Patheon and DSM Pharmaceutical Products that took place in March.
The new program will be rolled out at all sites globally and has already begun at the Greenville, N.C., USA; Linz, Austria; Cincinnati, Ohio, USA; and Toronto, Canada sites. The DP^x Operational Excellence program is focused on continuous improvement and performance for the organization and is centered on a commitment to Right First Time and On Time Delivery. DP^x will be executed through three drivers, including Lean and Six Sigma; visual management tools and performance boards to monitor key indicators; and employee engagement and empowerment. These three components allow quality, timeliness and efficiency to be measured and result in greater performance and employee satisfaction.
“We truly believe our commitment to excellence is second to none in the industry and drives our culture,” said Harry Gill, senior vice president, quality and operational excellence. “Our new Operational Excellence program, DP^x, will allow all sites across the globe to have the same mindset and focus, which will ensure that we are all delivering on our commitment to our company as well as our promise to our customers.”
Operational Excellence is a key component to our process of continuous improvement to our operations. DP^x is designed to support and streamline production which enables us to meet our customers’ needs right, on time and every time.
DPx Media Relations
Tel: (919) 226-3200
About DPx Holdings B.V.
DPx Holdings B.V. is the privately held parent company of the Patheon, DSM Fine Chemicals, and Banner Life Sciences businesses. The company is a leading provider of CDMO services, pharmaceutical products and products for other industries. Founded in 2014 as a result of a deal between JLL Partners and Royal DSM, DPx Holdings B.V. has three core business units, comprised of Patheon Pharma Services, DSM Fine Chemicals and Banner Life Sciences. With global headquarters in Durham, N.C., DPx Holdings B.V. has a footprint of more than 20 locations across North America, Europe, Latin America and Australia with more than 8,000 employees. DPx Holdings B.V. offers customers unsurpassed quality, integrated offerings and value through these three core business units. For more information visit www.patheon.com/DPx.
Patheon is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Patheon, a DPx Holdings B.V. business unit, encompasses the combined CMO capabilities and pharmaceutical product development services (PDS), as well as the Biosolutions and Biologics (BIO) business. For more information visit www.patheon.com.
About DSM Fine Chemicals
Announced in March 2014 as a business unit under the DPx umbrella, DSM Fine Chemicals provides active pharmaceutical ingredients (API) as well as ES/IM products and services that are primarily comprised of agricultural and crop protection chemicals. Its main focus is custom synthesis aimed at pharma and fine chemicals markets, of which the agro-chemicals sector is a primary focus. ES/IM also produces maleic anhydride and derivatives.
About Banner Life Sciences
Banner Life Sciences’ mission is to advance human health with innovation and creativity generating value for society and investors. Acquired by Patheon in December 2012, Banner Life Sciences is DPx’s proprietary products business. For more information visit www.bannerls.com.